End-stage renal disease (ESRD) also known as end-stage renal failure is the final, permanent stage of chronic kidney disease, where kidney function has declined to the point that the kidneys can no longer function on their own. In this condition, kidneys are only functioning at 10–15% of their normal capacity. A patient with end-stage renal failure must receive dialysis or kidney transplantation in order to survive for more than a few weeks.
Patients may experience a wide variety of symptoms as kidney failure progresses. These include fatigue, drowsiness, decrease in urination or inability to urinate, dry skin, itchy skin, headache, weight loss, nausea, bone pain, skin and nail changes, and easy bruising. Some of the risk factors for developing chronic kidney disease—that could ultimately lead to end-stage renal failure—include diabetes, high blood pressure, heart disease, drug abuse, blockages in the urinary tract, family history, inflammation, and some genetic disorders.
Diabetic nephropathy (DN) is one of the most common complications of diabetes and the leading cause of endstage renal disease (ESRD). Approximately 30–40% of diabetes mellitus patients in the world progress to ESRD, which emphasizes the effect of genetic factors on DN.
Get FREE sample copy at:
The End-Stage Renal Disease market report also covers emerging drugs, current treatment practices, End-Stage Renal Disease market share of the individual therapies, current and forecasted End-Stage Renal Disease Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current End-Stage Renal Disease treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
End-Stage Renal Disease Market Key Facts
As per the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in United States the overall prevalence of Chronic Kidney Disease (CKD) is in around 14% in general population. Over the years CKD may develop and lead to end stage renal disease (ESRD), i.e., Stage 5 CKD. At this stage most of the patients face kidney failure requiring dialysis or transplant for survival.
Based on the US Renal Data System (USRDS) annual data report, the prevalence of chronic renal failure between the years 2007 and 2011 was higher in women (15.1%) than in men (12.1%).
Key Benefits of End-Stage Renal Disease Market Report
End-Stage Renal Disease market report provides an in-depth analysis of End-Stage Renal Disease Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The End-Stage Renal Disease market report will help in developing business strategies by understanding the End-Stage Renal Disease Market trends & developments, key players and future market competition that will shape and drive the End-Stage Renal Disease market in the upcoming years.
The End-Stage Renal Disease market report covers End-Stage Renal Disease current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the End-Stage Renal Disease market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Treatment of ESRD entails high medical costs, and therefore, has huge market potential. Besides this, the market also comprises of therapies that are given as supportive care. The historical data supports the growth of ERSD market. The growth in market is attributed to the various aspects, such as ageing population, diabetic cases, transplantation and dialysis cases, etc. The trend is estimated to be persistent in forthcoming years with multibillion market size during the forecast period of 2020–2030.
The End-Stage Renal Disease market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted End-Stage Renal Disease market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of End-Stage Renal Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Kidney failure, also called end-stage renal disease (ESRD), is the last stage of chronic kidney disease. There is no cure for ESRD, but many people live long lives while on dialysis (hemodialysis or peritoneal dialysis) or after having a kidney transplant. According to the National Kidney Foundation, more than 17,000 kidney transplants were performed in the United States in 2014.
The End-Stage Renal Disease epidemiology section covers insights about historical and current End-Stage Renal Disease patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
End-Stage Renal Disease Drugs Uptake and Key Market Players
The End-Stage Renal Disease Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the End-Stage Renal Disease market or expected to get launched in the market during the study period. The analysis covers End-Stage Renal Disease market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Major players such as Rockwell Medical Technologies, Aronora, Dynavax Technologies Corporation, etc. are developing various preventive and supportive care therapies for the ESRD. Expected launch of emerging therapies such as intravenous triferic, AB002, HEPLISAV-B, and others for the treatment and prevention of End Stage Renal Disease (ESRD), shall contribute to the market growth of End Stage Renal Disease (ESRD) during the forecast period (2020–2030)
Table of Content
1. Key Insights
2. Executive Summary
3. End-Stage Renal Disease Competitive Intelligence Analysis
4. End-Stage Renal Disease Market Overview at a Glance
5. End-Stage Renal Disease Disease Background and Overview
6. End-Stage Renal Disease Patient Journey
7. End-Stage Renal Disease Epidemiology and Patient Population
8. End-Stage Renal Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. End-Stage Renal Disease Unmet Needs
10. Key Endpoints of End-Stage Renal Disease Treatment
11. End-Stage Renal Disease Marketed Products
12. End-Stage Renal Disease Emerging Therapies
13. End-Stage Renal Disease Seven Major Market Analysis
14. Attribute Analysis
15. End-Stage Renal Disease Market Outlook (7 major markets)
16. End-Stage Renal Disease Access and Reimbursement Overview
17. KOL Views on the End-Stage Renal Disease Market.
18. End-Stage Renal Disease Market Drivers
19. End-Stage Renal Disease Market Barriers
21. DelveInsight Capabilities
Get FREE sample copy at:
DelveInsight’s End-Stage Renal Disease (ESRD) – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of End-Stage Renal Disease (ESRD) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States